Team Experimental Immunology, PI Fredrik Wermeling

Research title:

Autoimmunity, Cancer immunotherapy and CRISPR/Cas9


Using experimental systems and patient material we study the immune system with a specific interest related to inflammation, autoimmune disease and cancer immunotherapy.

Research focus

A major part of the different projects in the lab relates to antibodies, neutrophils and T cells. We also spend a lot of effort into using CRISPR/Cas9 based custom screens as a discovery platform to understand complex biological processes and to identify novel drug targets. To facilitate the design of these screens, we have developed a software that we call Green Listed (Panda et al, 2017, Bioinformatics).

Currently several projects in the lab relates to our interest in signaling downstream of the IL-4 receptor (IL-4R) in myeloid cells. The basis for this interest was the unexpected finding that the expression of the IL-4R is essential for the activity of a drug (IVIG) used to treat patients with autoimmune disease, and that the expression of this receptor is highly regulated during inflammation (Anthony et al, 2011, Nature and Wermeling et al, 2013, PNAS).

Other projects are using in vivo CRISPR screens to identify central genes affecting the behavior of T cells and neutrophils in autoimmune disease and cancer.

Team members

Fredrik Wermeling, PI, PhD, Assistant Professor

Zsolt Kasza, PhD / Lab manager (2014- )

Sudeepta Kumar Panda, PhD / Postdoc (2014- )

Sanjay Boddul, PhD / Postdoc (2015- )

Guillermina Yanek Jiménez-Andrade, PhD / Postdoc (2016- )

Long Jiang, MD / PhD student (2016- )

Gustaf Wigerblad, PhD / Postdoc (2016- )

Wermeling lab June 2016. (Left to right: Sanjay Boddul, Yanek Jiménez-Andrade, Zsolt Kasza, Fredrik Wermeling, Sudeepta Panda). Photo Erik Holmgren.


Selected publications

Link to all publications on PubMed here.

(ORCID ID 0000-0001-9633-677X)


Green listed-a CRISPR screen tool.
Panda S, Boddul S, Jiménez-Andrade G, Jiang L, Kasza Z, Fernandez-Ricaud L, et al
Bioinformatics 2017 04;33(7):1099-1100

IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo.
Kritikou J, Dahlberg C, Baptista M, Wagner A, Banerjee P, Gwalani L, et al
Sci Rep 2016 08;6():30636

FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice.
Bosma M, Gerling M, Pasto J, Georgiadi A, Graham E, Shilkova O, et al
Nat Commun 2016 Apr;7():11314

Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling.
Wermeling F, Anthony R, Brombacher F, Ravetch J
Proc. Natl. Acad. Sci. U.S.A. 2013 Aug;110(33):13487-91

Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.
Anthony R, Kobayashi T, Wermeling F, Ravetch J
Nature 2011 Jun;475(7354):110-3

Invariant NKT cells limit activation of autoreactive CD1d-positive B cells.
Wermeling F, Lind S, Jordö E, Cardell S, Karlsson M
J. Exp. Med. 2010 May;207(5):943-52

Identification of a receptor required for the anti-inflammatory activity of IVIG.
Anthony R, Wermeling F, Karlsson M, Ravetch J
Proc. Natl. Acad. Sci. U.S.A. 2008 Dec;105(50):19571-8

Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus.
Wermeling F, Chen Y, Pikkarainen T, Scheynius A, Winqvist O, Izui S, et al
J. Exp. Med. 2007 Oct;204(10):2259-65